Schramm C, Fine DM, Edwards MA, Reeb AN, Krenz M. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling. Am J Physiol Heart Circ Physiol 302: H231-H243, 2012. First published November 4, 2011; doi:10.1152/ajpheart.00665.2011.-The identification of mutations in PTPN11 (encoding the protein tyrosine phosphatase Shp2) in families with congenital heart disease has facilitated mechanistic studies of various cardiovascular defects. However, the roles of normal and mutant Shp2 in the developing heart are still poorly understood. Furthermore, it remains unclear how Shp2 loss-of-function (LOF) mutations cause LEOPARD Syndrome (also termed Noonan Syndrome with multiple lentigines), which is characterized by congenital heart defects such as pulmonary valve stenosis and hypertrophic cardiomyopathy (HCM). In normal hearts, Shp2 controls cardiomyocyte size by regulating signaling through protein kinase B (Akt) and mammalian target of rapamycin (mTOR). We hypothesized that Shp2 LOF mutations dysregulate this pathway, resulting in HCM. For our studies, we chose the Shp2 mutation Q510E, a dominant-negative LOF mutation associated with severe early onset HCM. Newborn mice with cardiomyocyte-specific overexpression of Q510E-Shp2 starting before birth displayed increased cardiomyocyte sizes, heart-to-body weight ratios, interventricular septum thickness, and cardiomyocyte disarray. In 3-mo-old hearts, interstitial fibrosis was detected. Echocardiographically, ventricular walls were thickened and contractile function was depressed. In ventricular tissue samples, signaling through Akt/mTOR was hyperactivated, indicating that the presence of Q510E-Shp2 led to upregulation of this pathway. Importantly, rapamycin treatment started shortly after birth rescued the Q510E-Shp2-induced phenotype in vivo. If rapamycin was started at 6 wk of age, HCM was also ameliorated. We also generated a second mouse model in which cardiomyocyte-specific Q510E-Shp2 overexpression started after birth. In contrast to the first model, these mice did not develop HCM. In summary, our studies establish a role for mTOR signaling in HCM caused by Q510E-Shp2. Q510E-Shp2 overexpression in the cardiomyocyte population alone was sufficient to induce the phenotype. Furthermore, the pathomechanism was triggered pre-but not postnatally. However, postnatal rapamycin treatment could still reverse already established HCM, which may have important therapeutic implications.
protein tyrosine phosphatase; cell signaling; mammalian target of rapamycin THE NONRECEPTOR PROTEIN TYROSINE phosphatase Shp2 is ubiquitously expressed and acts as an essential modulator of multiple signaling pathways (12, 40) . For example, the presence of Shp2 is required for full and sustained activation of the extracellular signal-regulated kinase (ERK) pathway in the majority of receptor signaling cascades (1, 12, 13) . Therefore, it is not surprising that complete deletion of Shp2 in all tissues causes embryonic lethality around 9 days postconception (dpc) in mice (4, 35) , underlining Shp2's pivotal role in development.
To date, nearly 50 different mutations in the protein tyrosine phosphatase Shp2 have been identified in families with congenital heart disease (43) . Interestingly, mutations that lead to deletion or early truncation of the Shp2 protein have not been found in humans. However, numerous loss-of-function (LOF) mutations have been identified in LEOPARD Syndrome families (7, 20) . LEOPARD is an acronym for the manifestations of this syndrome: multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and deafness (14) . This syndrome is closely related to Noonan Syndrome and also known as Noonan Syndrome with multiple lentigines (NSML). Clinically of particular concern are the congenital heart defects in NSML patients, which include hypertrophic cardiomyopathy (HCM), valve and outflow tract malformations, coronary artery abnormalities, septal defects, arrhythmias, and sudden death (21) .
Which downstream signaling pathways are responsible for the effects of Shp2 LOF mutations in humans? Presumably, the critical step is that LOF mutants of Shp2 fail to dephosphorylate their normal targets. In normal cultured cardiomyocytes, Shp2 dephosphorylates focal adhesion kinase, resulting in reduced downstream signaling via protein kinase B (Akt) and mammalian target of rapamycin (mTOR), thus limiting cell size (24) . mTOR is the catalytic subunit of two distinct complexes, mTOR complex 1 (mTORC1) and mTORC2. Rapamycin, an antibiotic and immunosuppressant, inhibits functions of mTORC1, whereas mTORC2 is rapamycin-insensitive (31, 46) . mTORC1 is essential in the heart under physiological and pathological conditions (36, 45) , but unfortunately much less is known about the cardiac role(s) of mTORC2. Importantly, Akt/mTOR hyperactivation alone is sufficient to induce HCM (6, 26, 37) , indicating that this pathway is a very powerful stimulator of cardiac growth.
We hypothesized that this endogenous feedback loop is dysregulated in cardiomyocytes expressing LOF mutants of Shp2. The objective of our studies was to test the role of Akt/mTOR signaling in the HCM pathomechanism. Furthermore, we tested whether expression of a LOF mutation in Shp2 in cardiomyocytes alone is sufficient to induce HCM and investigated which time window is critical for triggering disease. For our mouse models, we selected the LOF mutation Q510E-Shp2, which is associated with a particularly aggressive form of biventricular HCM in pediatric patients (9, 42) . Few case reports have been published on this rare mutation (9, 11, 42) . However, all patients with this mutation reported to date suffered from severe HCM (9, 11, 22, 42), indicating that this LOF mutation is ideally suited for proof-of-principle studies of HCM mechanisms. Cardiomyocyte cultures and adenovirus construction. Rat neonatal hearts (days 1-3) were digested with collagenase (neonatal cardiomyocyte isolation kit; Worthington, Lakewood, NJ). Isolated cells were preplated on uncoated polystyrene dishes to remove fibroblasts and then plated on gelatin-coated dishes in M199 medium (initially with 10% bovine growth serum, then serumfree). FVB/N mouse cardiac mRNA was used as template for wild-type (WT)-Shp2 cDNA. The Q79R, Y279C, and Q510E mutations were introduced by site-directed polymerase chain reaction mutagenesis (QuikChange Mutagenesis Kit; Stratagene, Santa Clara, CA). After full-length sequencing of the construct and comparison with a published sequence (NCBI database NM_011202, Swiss-Prot: P35235.2), the cDNA was inserted into the pAdTrack-CMV vector for adenovirus generation (AdEasy Adenoviral Vector System; Stratagene). ␤-Galactosidase (␤-gal) adenovirus was obtained from Cell Biolabs (San Diego, CA).
MATERIALS AND METHODS

Animals
Protein tyrosine phosphatase assays. Shp2 proteins were immunoprecipitated from lysates of cultured adenovirus-infected rat neonatal cardiomyocytes, washed, and incubated in reaction buffer with src phosphopeptide (TSTEPQ-pY-QPGENL; Upstate, Billerica, MA). The resulting inorganic phosphate was quantified using a malachite green colorimetric reaction (Upstate) (19) .
Immunofluorescent staining and cell area measurements. For cell surface area determination, cultured rat neonatal cardiomyocytes were immunostained for troponin I (TnI), and all cardiomyocytes in each random field were planimetered (NIH ImageJ software) to obtain one average per field. Data from two to three independent isolates with at least three random fields per group and isolate were summarized. N numbers given in Fig. 1 denote the number of random fields. To assess proliferation, cardiomyocytes were labeled over 6 h with bromodeoxyuridine (BrdU) labeling reagent containing 5-bromo-2=-deoxyuridine and 5-fluoro-2=-deoxyuridine (Invitrogen) and immunostained (BrdU Staining Kit; Invitrogen).
Transgenic mice. To generate transgenic (TG) mice, Q510E-Shp2 cDNA was inserted in either the ␣-myosin heavy chain (MHC) or the ␤-MHC promoter cassette (33, 41) and injected in fertilized FVB/N oocytes. All lines were kept in a pure FVB/N background. One low-and two high-expressing lines with the ␤-MHC promoter construct (lines 1, 5, and 6) were used for experiments. Two ␣-MHC promoter construct lines with the lowest transgene expression were selected. Because the findings were identical, only results from one line are shown here. Nontransgenic (NTG) littermates were always used for controls. For postnatal drug treatments, rapamycin (LC Laboratories, Woburn, MA) dissolved in dimethyl sulfoxide was injected daily at 2 mg/kg ip into nursing dams. For vehicle controls, dams were injected with equivalent volumes of dimethyl sulfoxide. Weaned pups or adult mice received 2 mg/kg rapamycin intraperitoneally daily or equivalent volumes of dimethyl sulfoxide.
Histological and morphometric analyses of the hearts. For cardioplegic arrest in end-diastole, mice underwent deep inhalation anesthesia using 2-3% isofluorane with 0.6 liters flow of O 2. Hearts were perfused through the apex with 4% paraformaldehyde in PBS containing 25 mM KCl and 5% dextrose. Sections through these hearts used for quantifying ventricular wall thicknesses were taken exactly in the middle of the heart where the right-and left-ventricular cavity areas were largest, and leaflets of both mitral and tricuspid valves were seen in the same plane. Free wall dimensions were measured exactly halfway between apex and atrioventricular valve leaflet insertion. Septum thicknesses were measured exactly halfway between the apex and atrioventricular valve leaflet insertion (termed middle septum) and at the border between the basal and middle thirds of the longitudinal septum length (termed basal septum). Sections were stained with fluorescently labeled wheat germ agglutinin (WGA; Invitrogen, Carlsbad, CA), hematoxylin and eosin, or Gomori's Trichrome staining. To assess proliferation, dams were injected with 10 ml/kg BrdU labeling reagent at 14.5 dpc, and embryos were harvested after 2 h. To detect cardiomyocyte disarray, sections were immunostained for TnI. N numbers given in Figs. 2-7 denote the number of individual hearts.
Echocardiography. Echocardiograms were performed under inhalation anesthesia (1.2-1.8% isofluorane, 0.6 liter flow of O 2) using a GE Vivid 7 ultrasound system (GE Healthcare, Buckinghamshire, UK) with a 12-mHz transducer. The echocardiographer was blinded to the treatment groups. M-mode echocardiography was performed using the parasternal short-axis view of the left ventricle (LV). The guidelines of the American Society of Echocardiography were used for measurement of the LV end-diastolic and end-systolic diameters, and septal and posterior wall thickness. Fractional shortening was determined from the measurements of LV chamber dimensions and calculated by (LV internal diameter in diastole Ϫ LV internal diameter in systole)/LV internal diameter in diastole. Images were captured digitally, and six consecutive cardiac cycles were measured and averaged for each animal.
Protein analyses. The following antibodies were used: Shp2 C-18, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology, Santa Cruz, CA); FLAG (Sigma-Aldrich, St. Louis, MO); TnI, phosphohistone H3 (Millipore, Billerica, MA); mTOR, phospho-mTOR S2481, p70S6 kinase (p70S6K), phosphop70S6K T389, Akt, phospho-Akt S473, phospho-Akt T308, S6, phospho-S6 S240/244, p44/42 mitogen-activated protein kinase (MAPK), phospho-p44/42 MAPK T202/Y204, glycogen synthase kinase 3␤ (GSK3␤), and phospho-GSK3␣/␤ S21/9 (Cell Signaling Technologies, Beverly, MA); and Alexa-conjugated secondary antibodies (Invitrogen). For protein extracts, flash-frozen mouse ventricles or cultured rat neonatal cardiomyocytes were homogenized in lysis buffer [150 mM NaCl, 10 mM Tris, pH 7.4, 1% Triton X, 1ϫ Halt Protease & Phosphatase Inhibitor Cocktail (Sigma-Aldrich)]. Phosphorylated and total protein bands were quantified using the Bio-Rad ChemDoc imaging system or Amersham Hyperfilm (GE Healthcare) and QuantityOne software (BioRad).
RNA analysis. RNA was extracted from mouse ventricles (TRIzol Reagent; Invitrogen) for first-strand DNA synthesis (Superscript III First-Strand Synthesis System; Invitrogen). Quantitative reverse transcription-polymerase chain reactions (qRT-PCR) were performed using a Cepheid SmartCycler with Sybr green intercalating dye (Takara SYBR Premix Ex Taq; Takara, Otsu, Shiga, Japan). Primer sequences were obtained from Roche's Universal ProbeLibrary. The relative expression levels were determined using the 2 Ϫ⌬⌬CT method with GAPDH as the housekeeping gene (23) .
mTOR kinase activity assays. The enzymatic activity of mTOR was determined with the K-LISA mTOR Activity Kit (EMD Chemicals, Gibbstown, NJ). In short, mTOR protein was immunoprecipitated from mouse ventricular tissue. Purified proteins were then incubated with a p70S6K-GST fusion protein as substrate together with ATP. The phosphorylated substrate was detected with anti-phopspho-p70S6K (T389) antibody, followed by detection with horseradish peroxidase antibody and tetramethylbenzidine substrate. Relative activity was determined by reading the absorbance at 450/540 nm.
Data normalization and statistical analysis. Data were normalized to control as follows: all measurements obtained in the control group were averaged, and then all data (including individual measurements from the control group) were divided by this average. Bar graphs for activity assays, cardiomyocyte surface areas, Western blot signal quantifications, and mRNA expression are shown as means Ϯ SE after this normalization. In all other cases, raw data are represented as means Ϯ SE. Unpaired Student's t-tests were used for comparisons of two groups, and two-way ANOVA (Fisher least-significant difference post hoc test) was used to compare groups in Table 1 . P Ͻ 0.05 was considered significant.
RESULTS
Q510E-Shp2 is a dominant-negative LOF mutation and increases cardiomyocyte size in vitro.
To generate various Shp2 proteins for in vitro phosphatase activity assays, rat neonatal cardiomyocytes were infected with adenoviruses encoding either WT-Shp2 with or without a COOH-terminal FLAG tag, the Flag-tagged LOF mutants Q510E-Shp2 or Y279C-Shp2, or the gain-of-function (GOF) mutant Q79R-Shp2. Phosphatase activities of Y279C-and Q79R-Shp2 have been determined previously (17, 19) and therefore served as negative and positive controls. Lysates from these cultures underwent Western blotting to confirm that Shp2 protein levels were equivalent across all groups (Fig. 1A , inset, row on top). From these lysates, the various Shp2 proteins were immunoprecipitated with anti-Shp2 or anti-Flag. Equal amounts of the purified Shp2 proteins (as verified by Western blot, Fig. 1A , inset, row on bottom) were incubated with a Src phosphopeptide to assess phosphatase activities. The activities of the respective Shp2 proteins were normalized to that of untagged WT-Shp2. Tagged WT-Shp2 displayed the same activity as the untagged protein, thus excluding any interference of the tag itself with enzymatic activity. Q510E-Shp2 and Y279C-Shp2 exhibited only 9.8 and 4.9% of the activity measured with untagged WT-Shp2, respectively, whereas Q79R-Shp2's activity was 4.4-fold increased as expected (Fig. 1A , bar graph). To test whether Q510E-Shp2 expression has dominant-negative effects on ERK signaling as previously reported for other LOF mutations in Shp2 (17), we assessed ERK1/2 phosphorylation after serum stimulation of neonatal rat cardiomyocyte cultures (Fig. 1B) . As expected, ERK1/2 activation in response to serum was downregulated by 22% in the presence of Q510E-Shp2 compared with control cultures expressing ␤-gal or WT-Shp2 (quantification shown in Fig. 1C) .
Next, cardiomyocyte surface areas were determined after infection with ␤-gal, Q510E-, WT-, and Q79R-Shp2 adenoviruses. High infection efficiency was confirmed by immunohistochemistry (Fig. 1, D and E) . Western blots were used to ensure that equivalent amounts of WT-, Q79R-, and Q510E-Shp2 protein were present (Fig. 1F) . To quantify cell sizes and distinguish cardiomyocytes from potential fibroblast contamination, cells were immunostained for TnI (Fig. 1, H and I) . Q510E-Shp2 expression resulted in a 51% increase in cardiomyocyte size. WT-or Q79R-Shp2 did not alter cardiomyocyte size (Fig. 1G) . Because TnI is not a cell surface marker per se, in an additional set of experiments, a double staining with WGA and anti-TnI was used (data not shown). We found that the TnI staining quantitatively underestimated cardiomyocyte surface area by ϳ3-5%, but, qualitatively, the WGA and TnI stainings showed the exact same results. We also tested whether Q510E-Shp2 expression affected cardiomyocyte proliferation in culture using BrdU incorporation. No significant differences were found: 2.84 Ϯ 0.37% of nuclei in Q510E-Shp2-infected cells and 2.75 Ϯ 0.43% of nuclei in noninfected cells were BrdU-positive.
Transgenic Q510E-Shp2 expression starting before birth induces HCM. Because cultured neonatal cardiomyocytes may not recapitulate all aspects of HCM correctly, we generated mice for in vivo analyses. The dominant-negative biochemical characteristics of Q510E-Shp2 allowed us to take an overexpression approach. Our goal was to dissect tissue-and developmental window-specific effects of Q510E-Shp2 expression by using different cardiac promoter constructs. We first created TG mice using the ␤-MHC promoter to drive transgene expression starting around 11 dpc (30), termed ␤-MHC-Q510E-Shp mice. Multiple lines were obtained with expression levels ranging from 2.5-to 12-fold over endogenous levels at postnatal day 1 ( Fig. 2A) .
Q510E-Shp2 expression levels were compared at different ages. The endogenous ␤-MHC promoter shuts down after birth (33) . However, the transgenic ␤-MHC promoter lacks some of the endogenous regulatory elements and therefore may fail to respond to developmental cues (33) . In all lines included in this study, Q510E-Shp2 expression remained stable during the first 3 wk after birth (Fig. 2B ). Expression profiles were followed until 4 mo of age in all lines, when only a small decrease in Q510E-Shp2 expression was noted (Fig. 2D) . However, progressive cardiac disease might have led to upregulation of the transgenic ␤-MHC promoter, thus counteracting developmental signals. Therefore, we assessed the endogenous ␤-MHC promoter activity via qRT-PCR. Because ␤-MHC mRNA expression was normal in 5-wk-old hearts (Fig. 2C) , it is unlikely that transgenic promoter activity was upregulated due to any other signals. Therefore, Q510E-Shp2 was stably and continuously expressed after birth with only a minor decline in adult mice.
TG mice were born at the expected Mendelian ratios, and survival rates were normal until at least 8 mo of age (data not shown). No gender-specific effects were noted. Already at birth, the gross morphology of the TG hearts differed substantially from the NTG controls. Both LV and right ventricle (RV) exhibited a rounded shape and enhanced interventricular groove together with enlarged atria (Fig.  2E) . In histological sections from 1-day-old TG hearts, the interventricular septum appeared to be thickened (Fig. 2F) , and small membraneous or muscular ventricular septal de- Fig. 1 . Q510E-Shp2 is a dominant-negative loss-of-function (LOF) mutation that increases cardiomyocyte size in culture. A: Shp2 proteins were purified from cultured neonatal rat cardiomyocytes expressing wild-type (WT)-Shp2 with or without FLAG (Fl) tag, the LOF mutants Q510E-Shp2 and Y279C-Shp2, or the gain-of-function (GOF) mutant Q79R-Shp2. First, protein expression was confirmed in cell lysates by immunoblot (IB, row on top). After immunoprecipitation (IP) with either anti-Shp2 or anti-Flag, aliquots of the precipitates were probed for Shp2 to quantify how much of the various Shp2 proteins had been extracted (row on bottom). The immunoprecipitates were used to measure phosphatase activities. Similar to Y279C, Q510E decreased phosphatase activity, whereas Q79R increased catalytic activity (data were normalized to untagged WT-Shp2). B and C: cardiomyocytes that were either expressing ␤-galactosidase (␤-gal), WT-Shp2, or Q510E-Shp2 were harvested under serum-free conditions or 30 min after addition of 10% bovine growth serum. Quantification of the Western blot signal intensities showed downregulated extracellular signal-regulated kinase (ERK) 1/2 activation by Q510E-Shp2, whereas overexpression of WT-Shp2 did not alter ERK1/2 activity. D and E: rat neonatal cardiomyocytes were infected with adenoviruses encoding either ␤-gal or Q510E-Shp2. After infection (48 h), cells were immunostained for Shp2. On average, 75-85% of cardiomyocytes demonstrated increased levels of total Shp2. F: virus doses of Q510E-Shp2, Q79R-Shp2, and WT-Shp2 were titrated using Western blots. A representative blot for dose comparisons is shown. The first two lanes with uninfected samples were overloaded deliberately to ensure a clear signal from endogenous Shp2. In this example, multiplicities of infection (MOIs) of 3 for Q510E-Shp2, 7 for Q79R-Shp2, and 6 for WT-Shp2 were chosen for subsequent determination of cardiomyocyte sizes. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. G: quantification of cardiomyocyte cell surface areas after staining for troponin I (TnI). Q510E-Shp2, but not ␤-gal, WT-Shp2, or Q79R-Shp2, expression significantly increased cell surface areas. H-I: images of cultured neonatal rat cardiomyocytes expressing either ␤-gal or Q510E-Shp2 and immunostained for TnI. fects were found in about one-half of the TG hearts (5/11 in TG, 0/12 in NTG; Fig. 2G ). TG heart morphology was similar in all lines regardless of the level of Q510E-Shp2 overexpression.
For quantification of ventricular wall thicknesses in neonatal mice, 2-wk-old hearts were arrested in end-diastole before fixation. The interventricular septum as measured in two different locations was 1.4-fold thicker in Q510E-and Shp2-expressing hearts (Fig. 3A) . This did not regress over time; at 3 mo of age, septum thickness remained increased compared with NTG (Fig. 3C) . The abnormal morphology of the TG hearts also did not change in adulthood (Fig. 3B) . Sections through newborn hearts were stained with WGA to quantify cardiomyocyte sizes. Transverse cardiomyocyte cross-sectional areas were already increased in newborn TG mice (Fig.  3, D-G ). There were no differences between low-and highexpressing lines.
To assess whether HCM was already present at embryonic stages, histological sections through 13.5 dpc hearts were prepared. There were no differences in interventricular septum or free wall thicknesses (Fig. 4, A and B) . However, the ventricles already displayed a rounded shape. Next, we assessed indexes of cardiomyocyte proliferation. At 14.5 dpc, the ratio of BrdU-positive nuclei was not altered significantly in any region of the TG hearts, although a consistent trend toward lower numbers was observed (Fig.  4, C-E) . We also stained newborn heart sections for phosphohistone H3 to measure proliferation immediately after birth. In the interventricular septum, 1.36 Ϯ 0.42% of nuclei showed solid staining for phosphohistone H3 in NTG hearts and 0.73 Ϯ 0.25% in TG hearts. Again, this trend was not statistically significant.
To determine whether the TG hearts displayed physiological or pathological cardiac hypertrophy, we determined the expression levels of markers of the fetal gene program and the extent of cardiomyocyte disarray and cardiac fibrosis. At birth, brain natriuretic peptide, atrial natriuretic factor, and ␣-skeletal actin, but not ␤-MHC, expressions were increased significantly (Fig. 4F) . Cardiomyocyte disarray was already detectable in newborn hearts (Fig. 4, G and H) . In older mice, the extent of disarray was increased compared with newborn hearts (data not shown). Mild interstitial fibrosis was not observed until 3 mo of age. Isolated foci of fibrosis were found in the septum, in the LV free wall, and in the apex (Fig. 4, I-L) . Fibrosis was also increased in perivascular regions (Fig. 4, M and N) . . Atria were enlarged, and both the right (RV) and left (LV) ventricles had a rounded shape with an emphasized interventricular groove (*). F: sections through newborn hearts from line 6 [hematoxylin and eosin (H&E)]. Ventricular walls both in nontransgenic (NTG) and transgenic (TG) appear very thick. This is due to the fact that the hearts were not arrested in end-diastole before fixation due to their small size, thus not permitting exact quantification. However, in these sections, the interventricular septum also appeared thicker in TG hearts compared with NTG as seen in older mice. G: sections through newborn hearts from line 5 (H&E). These sections were not cut through the center of the hearts as in F but further ventral to demonstrate a membranous ventricular septal defect in the TG heart (arrow).
The functional consequences of Q510E-Shp2 expression were determined via echocardiography in 3-mo-old male mice (Table 1 and Fig. 5D ). In TG, left atrial diameters were increased by 37%, LV fractional shortening was depressed significantly by 20%, and end-diastolic dimensions of the interventricular septum and the LV posterior wall were both significantly increased by 29 and 22%, respectively. Q510E-Shp2 expression hyperactivates signaling through Akt/mTOR. Because Shp2 is known to control Akt/mTOR signaling in cardiomyocytes (24), we tested whether Q510E-Shp2 expression affected activation of this pathway in the in vivo mouse heart. Q510E-Shp2 expression increased Akt, mTOR, and p70S6K phosphorylation over twofold (Fig. 5, A  and B) . Importantly, the kinetic activity of mTOR extracted from TG hearts was increased by 24% (Fig. 5C ). We also determined Akt/mTOR phosphorylation status in isolated neonatal rat cardiomyocytes after infection with Q510E-Shp2 adenovirus. Similar to the in vivo findings, Q510E-Shp2 expression increased Akt, mTOR, and p70S6K activity in vitro (data not shown).
Rapamycin treatment reverses Q510E-Shp2-induced HCM. Next, we tested whether rapamycin reverses the HCM phenotype in our model. We chose the dose of 2 mg·kg Ϫ1 ·day Ϫ1 since this dose has previously been shown to counteract pressure overload-induced hypertrophy in mice (27, 38) . Prenatal rapamycin administration leads to embryonic/fetal demise; therefore, rapamycin or vehicle was given to nursing dams starting after delivery. Five days of treatment were sufficient to normalize cross-sectional cardiomyocyte sizes in the pups (Fig. 6, A-E) . Next, we extended the treatments in new groups to 2 wk. Rapamycin delivery via maternal milk nearly halved the offsprings' body weights without significant differences between NTG and TG pups (vehicle group 9.9 Ϯ 0.5 g in NTG and 8.8 Ϯ 0.6 g in TG; rapamycin group 5.8 Ϯ 0.4 g in NTG and 5.3 Ϯ 0.5 g in TG, n ϭ 9 -13). In vehicle-treated TGs, heart-to-body weight ratios were increased by 32% (Fig. 6F) . Rapamycin abolished this difference in heart-to-body weight ratio and normalized septum thickness in the TGs (Fig. 6G) . We confirmed that rapamycin effectively reversed Q510E-Shp2's effects on p70S6K and S6 phosphorylation using Western blots (Fig. 6H) . In cultured neonatal cardiomyocytes, Q510E-Shp2 blunted ERK1/2 activation in response to serum stimulation (Fig. 1) . We therefore assessed the degree of ERK1/2 phosphorylation in ventricular samples from ␤-MHC-Q510E-Shp2 mice. Q510E-Shp2 expression resulted in increased levels of active ERK1/2. However, rapamycin treatment of the TG animals did not affect the extent of ERK1/2 hyperactivation (Fig. 6H) .
Because rapamycin promotes autophagy, we reassessed Q510E-Shp2 expression levels and two autophagy markers in mice receiving rapamycin from birth until 5 wk of age. Importantly, Q510E-Shp2 expression levels remained unchanged (Fig. 6I) . During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involv- ing Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles. Because the amount of LC3-II correlates with the extent of autophagosome formation (16), we used this as an indicator of autophagy. Comparing NTG and TG hearts without rapamycin, Q510E-Shp2 expression decreased conversion of LC3B-I to LC3B-II, consistent with mTOR's known inhibitory effects on autophagy (Fig. 6I) . Rapamycin treatment reversed these changes but did not increase LC3B-II to levels above those seen in untreated NTGs. Furthermore, no changes in Beclin-1 levels were detectable. This indicates that rapamycin did not exert its beneficial effects by shutting down Q510E-Shp2 protein expression or by inducing excessive autophagy.
Last, we wanted to determine to which extent rapamycin can reverse HCM in adult mice if the treatment was started not immediately after birth but much later. Rapamycin or vehicle was administered daily to male mice from 6 to 11 wk of age. Cardiac dimensions and contractile function were then assessed by echocardiography. Both septum and LV posterior wall dimensions were completely normalized by rapamycin (Table 1 and Fig. 5D ), thus exactly matching the histological findings after 5-14 days of early treatment. Both in NTG and TG animals, rapamycin treatment nonsignificantly depressed fractional shortening compared with vehicle-treated controls.
Transgenic Q510E-Shp2 expression starting after birth does not induce HCM. We previously found that the GOF mutation Q79R-Shp2 only triggered a cardiac phenotype if expression started before birth (29) , suggesting that the time window of expression is critical for the cardiac phenotype. Fig. 4 . Q510E-Shp2 expression starting before birth causes cardiomyocyte disarray and interstitial fibrosis and upregulates the fetal gene program. A and B: sections through the center of embryonic [13.5 days postconception (dpc)] hearts demonstrating no differences in interventricular septum or free wall thicknesses but already a rounded shape with an emphasized interventricular groove (H&E staining, line 5). C and E: bromodeoxyuridine (BrdU) labeling of the myocardium at 14.5 dpc. No significant changes were found in any region of the TG hearts, but a consistent trend toward lower numbers of BrdU-positive nuclei was observed. F: mRNA expression in newborn hearts assessed by qRT-PCR. Brain natriuretic peptide (BNP), atrial natriuretic factor (ANF), and ␣-skeletal actin (␣-SkA) were increased significantly in TG hearts (line 6). G and H: sections through NTG (G) and TG (H) newborn hearts immunostained for TnI to visualize cardiomyocyte disarray in TG. I-N: sections through the LV of 3-mo-old NTG (I, K, and M) and the directly corresponding areas in TG hearts (J, L, and N) after Gomori's Trichrome staining (line 6). Expression of Q510E-Shp2 resulted in isolated foci of interstitial fibrosis, in particular in perivascular areas. Scale bars: A and B, 500 m; C and D, 50 m; G-N, 100 m.
Therefore, we created a second mouse model to test whether postnatal cardiomyocyte-specific expression of Q510E-Shp2 was sufficient to induce HCM using the ␣-MHC promoter. During embryonic stages, ␣-MHC promoter activity is very low (30) , and, as expected, we could not detect any cardiac Q510E-Shp2 protein at 17.5 dpc (Fig. 7A) . After birth, transgene expression in the ␣-MHC-Q510E-Shp2 mice was robust (Ն10-fold, Fig. 7B ).
Heart morphology (Fig. 7C) and heart-to-body weight ratios (Fig. 7E) were normal in adult ␣-MHC-Q510E-Shp2 mice.
Cardiomyocyte cross-sectional areas were increased slightly, but this was only significant in the RV (Fig. 7D ). This small increase was not sufficient to result in increased wall or chamber dimensions and was not accompanied by any of the classic hallmarks of HCM such as disarray or fibrosis. Echocardiographically, we did not note any significant alterations in cardiac dimensions or contractile function (Table 2 ). Furthermore, we tested whether Q510E-Shp2 expression starting after birth also increased Akt/mTOR signaling. In Western blots, both Akt and p70S6K were 1.6- 473 and threonine (T) 308, mTOR, and p70S6 kinase (p70S6K), but no difference in glycogen synthase kinase (GSK) 3␣/␤ phosphorylation (p). B: signal intensities were quantified and expressed as the relative ratios of phospho/total protein signal. C: kinase activity of mTOR extracted from TG ventricular tissues was increased compared with NTG samples. D: cardiac dimensions and contractile function in 11-wk-old mice assessed by echocardiography. End-systolic and end-diastolic wall thickness measurements are indicated by arrows. In TG, end-diastolic septum and LV free wall thicknesses were increased. This was normalized by rapamycin treatment. to 2.2-fold hyperactivated in 2-mo-old ␣-Q510E-Shp2 hearts (Fig. 7, F and G) .
DISCUSSION
The objective of this study was to evaluate time and tissue specificity of the prohypertrophic effects of the LOF mutation Q510E-Shp2 in vivo and to investigate the role of Akt/mTOR signaling in the disease process. Expression of Q510E-Shp2 in cardiomyocytes starting before birth resulted in neonatal-onset HCM that was accompanied by upregulation of Akt/mTOR signaling. Importantly, rapamycin treatment effectively reversed the disease phenotype. This indicates that mTOR activation plays a critical role in the underlying disease mechanism.
Because Q510E-Shp2 displayed dominant-negative characteristics in our in vitro assays, we chose a TG approach to generate in vivo models. Mice from multiple lines exhibited identical phenotypes, which excludes the possibility of inser- Fig. 6 . Rapamycin treatment normalizes cardiomyocyte sizes, heart-to-body weight ratios, and interventricular septum thickness but does not alter expression levels of Q510E-Shp2. A-E: WGA-stained sections through the septum and quantification of cross-sectional areas in different regions of the heart (lines 5 and 6). Five days of rapamycin treatment decreased cardiomyocyte size in newborn TG ␤-MHC-Q510E-Shp2 mice to NTG levels. F: heart-to-body weight ratios of NTG and TG offspring after 2 wk of vehicle/rapamycin administration to nursing dams. In the vehicle groups, the heart-to-body weight ratio was increased significantly in TG pups. This difference was abolished in rapamycin-treated animals. G: quantification of septum thickness in sections through NTG and TG hearts after 2 wk of vehicle/rapamycin administration. In the vehicle groups, septum thickness was increased significantly in TG pups. This difference was abolished in rapamycin-treated animals. H: Western blots showing significantly increased phosphorylation of p70S6K and S6 in vehicle-treated TGs and reversal of this increase in hearts from TG animals that received rapamycin. In contrast, increased phosphorylation of ERK1/2 in Q510E-and Shp2-expressing hearts was not affected by rapamycin treatment (all samples from line 6 littermates). I: Western blot to demonstrate unchanged overexpression of Q510E-Shp2 in ventricular cardiomyocytes from 5-wk-old line 6 mice treated with rapamycin (rapa) since birth. Q510E-Shp2 expression decreased LC3B-II expression; this was reversed by rapamycin treatment. J: beclin-1 levels were not affected by Q510E-Shp2 expression or rapamycin treatment.
tional mutagenic effects. Regarding potential concerns about increased gene dose, we previously conducted detailed experiments in WT-Shp2 overexpressors using both the ␤-MHC and the ␣-MHC promoter constructs (29) . In both cases, robust overexpression of WT-Shp2 did not induce any morphological or functional alterations. Similarly, WT-Shp2 overexpression in cultured cardiomyocytes did not alter cardiomyocyte size in our current study. Furthermore, we have previously employed TG approaches for two other mouse models with a different Shp2 mutation, and in both cases the TG cardiac phenotypes were very similar to the results from another group using gene-targeting approaches (2, 3, 18, 29) .
Very recently, another gene-targeting study has provided additional proof that our TG approach is valid for testing the effects of Q510E-Shp2. In parallel to our studies, a knock-in model was created in which the Shp2 LOF mutation Y279C was introduced into the mouse genome (25) . Y279C-Shp2-expressing mice developed HCM, but this phenotype was milder than in our study and became evident only late in adulthood. Our mouse model is the first to recapitulate the neonatal-onset type of HCM often seen in patients with Shp2 LOF mutations, including Y279C (8, 22) . Despite the profound differences between the two models, HCM in both our TG model and the Y279C-Shp2 knock-in model was reversed by rapamycin. The two mouse studies therefore complement each other and together provide strong support that signaling through mTOR is essential for the pathomechanism triggered by Shp2 LOF mutations.
An important aspect is the question of the relative roles of mTORC1 and mTORC2 in the disease process triggered by Q510E-Shp2. In the current study, we provide evidence that mTORC1 activity is upregulated. To date, there are no reliable assays for specific assessment of mTORC2 activity. Akt was hyperphosphorylated at the mTORC2-specific residue S473, suggesting that mTORC2 activity is upregulated in our model as well. In general, only mTORC1, but not mTORC2, is rapamycin-sensitive. However, prolonged treatment with rapamycin does inhibit mTORC2 in many cell types (34) ; therefore, we cannot exclude a contributing role of mTORC2 at this point.
Two recent in vitro studies have indicated that LOF mutations in Shp2 exert prohypertrophic effects by signaling through phosphatidylinositol 3-kinase/Akt/GSK3␤ (10, 15). In contrast, GSK3␣/␤ phosphorylation was unchanged in our Western blots to demonstrate Q510E-Shp2 overexpression in ventricular cardiomyocytes from 8-mo-old TG mice. C: histological sections through 8-mo-old mouse hearts arrested in end-diastole before fixation showed that expression of Q510E-Shp2 starting after birth did not affect ventricular dimensions or wall/septum thicknesses. D: cardiomyocyte cross-sectional areas were determined using WGA staining. In TG 8-mo-old mice, cell areas were increased slightly, but these differences were only statistically significant in the RV wall. E: heart-to-body weight ratios were not affected by Q510E-Shp2 expression either at 3 or 8 mo of age. F: Western blots from 2-mo-old hearts showing significantly increased phosphorylation of Akt at S473 and T308 and p70S6K. G: signal intensities were quantified and expressed as the relative ratios of phospho/total protein signal.
model. Most likely, these discrepancies are due to the substantial methodological differences between the in vitro and in vivo models. Interestingly, GSK3␣ (but not GSK3␤) hyperactivation was reported in the Y279C-Shp2-expressing mice (25) . In that study, a low-dose treatment with rapamycin that did not affect Akt/GSK3 signaling was equally effective against HCM as a high-dose rapamycin protocol. The authors therefore concluded that rapamycin's beneficial effects are primarily mediated via mTOR inhibition. Considering the lack of GSK3␣/␤ hyperphosphorylation in this study, our data also suggest that GSK3 is unlikely to play a major role in the in vivo pathomechanism.
Consistent with our findings, TG overexpression of active Akt in cardiomyocytes starting after birth is sufficient to induce cardiac hypertrophy (6, 26, 37) . Therefore, we would have expected to see HCM in our ␣-MHC-Q510E-Shp2 mice as well. Western blots revealed that signaling through Akt/mTOR was upregulated in the ␣-MHC-Q510E-Shp2 mice. This argues against the possibility that compensatory effects (such as, for example, increased activity of Akt-specific phosphatases) were counteracting the effects of Q510E-Shp2. Based on our findings, we suspect that Shp2 plays an important homeostatic role in the myocardium during embryonic stages that is different from its role in the adult myocardium and likely involves other pathways in addition to Akt/mTOR.
It has now emerged that many cardiomyopathic effects are not only time but also tissue specific. Recent studies focusing on the effects of Shp2 LOF mutations in the heart do not allow for a clear distinction of whether or not the underlying pathomechanism is cardiomyocyte-dependent. This question is of high interest, since, recently, cardiac fibroblast-specific mechanisms have been identified that are critical in the respective pathomechanism (44) . In the Y279C-Shp2 knock-in model (25) , both cardiomyocytes and cardiac fibroblasts expressed the mutant Shp2 protein. In cardiomyocyte cultures as used in our current study and by others (10) , small amounts of contaminating fibroblasts are difficult to avoid. Similarly complicated is a recent very elegant study using fibroblasts from patients carrying the T468M mutation in Shp2 (5) . From these fibroblasts, reprogrammed induced pluripotent stem cells were generated and differentiated into cardiomyocytes. These cells were increased in size, but again the experimental approach prohibits distinction between fibroblast-and cardiomyocytespecific effects. In our model, cardiomyocyte-specific expression of Q510E-Shp2 was sufficient to induce the HCM phenotype. This does not exclude that fibroblasts may be contributing to the phenotype in patients, but our findings support the notion that the disease process is triggered primarily in the cardiomyocyte population.
Because Shp2 modulates numerous signaling cascades, it is possible that other pathways, not just Akt-related signaling, support the development of the HCM phenotype. We noted that ERK1/2 activity was increased in TG hearts. At first sight, these data contradict our findings in isolated neonatal cardiomyocytes, in which no baseline difference in ERK1/2 activation was detectable and the response to serum stimulation was blunted by Q510E-Shp2. However, cardiomyocyte cultures constitute a highly reductionist system that reflects the biochemical characteristics of mutant Shp2 but may not recapitulate all aspects of HCM. Alternatively, increased ERK1/2 activation in vivo could be a secondary response, which may be triggered by independent stress signals in the hypertrophied ␤-MHC-Q510E-Shp2 hearts. We tested the level of ERK1/2 activation in rapamycin-treated TG hearts and found that rapamycin did not affect the degree of ERK1/2 hyperactivation. Therefore, we believe that ERK signaling does not play a major role in the disease mechanism. However, only comprehensive future experiments regarding the necessity of ERK signaling downstream of Q510E-Shp2 will elucidate the clinical relevance of the ERK pathway.
Taken together with the very recent study showing rescue of the HCM phenotype by rapamycin in Y279C-Shp2-expressing hearts (25) , our data provide strong support that mTOR inhibition with rapamycin or possibly newer derivatives may be a feasible new therapeutic avenue for patients with Shp2 LOF mutations and severe HCM. In various other hypertrophy models as well as humans, rapamycin attenuates HCM (27, 32, 38) . However, rapamycin has negative inotropic effects in our study as well as in other models (28) . Because mTOR mitigates adverse outcomes after pressure overload (39) , chronic mTOR inhibition may have very detrimental effects. This is further underlined by two independent studies showing that ablation of mTOR or raptor leads to fatal dilated cardiomyopathy (36, 45) . Consequently, rapamycin administration to patients with severe HCM and compromised contractile function may not be advisable. However, the Y279C-Shp2 mouse model displayed hypercontractility in early disease stages that was effectively normalized by rapamycin (25) . Therefore, the success of rapamycin treatment in patients with LOF mutations in Shp2 may depend on how early the diagnosis is made and treatment initiated, which would be an important consideration for the design of future clinical trials.
